Skip to main content
$28.81 -$0.56 (-1.9%)

03:14 PM EDT on 09/26/22

Gsk Plc (NYSE:GSK)

CAPS Rating: 4 out of 5

The Company is a global healthcare group which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter medicines and health-related consumer products.

Current Price $28.81 Mkt Cap $57.8B
Open $29.06 P/E Ratio 12.86
Prev. Close $29.36 Div. (Yield) $1.53 (5.2%)
Daily Range $28.47 - $29.27 Volume 7,169,144
52-Wk Range $28.47 - $58.71 Avg. Daily Vol. 7,568,913

Caps

How do you think NYSE:GSK will perform against the market?

Add Stock to CAPS Watchlist

All Players

1,384 Outperform
81 Underperform
 

All-Star Players

280 Outperform
17 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NYSE:GSK Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

brittlee43 (< 20)
Submitted February 07, 2020

Good dividends, strong company

Funzer (< 20)
Submitted November 16, 2007

GSK is revising Avandia product label to reflect negative events such as myocardial ischemia. Since there is no reduction in cardiovascular risks for diabetics, this reduces the long term outlook for the profitablity of this drug product and GSK.

Recent Community Commentary

Read the most recent pitches from players about GSK.

Recs

0
Member Avatar 1russianguy (87.08) Submitted: 6/13/2022 11:27:59 AM : Outperform Start Price: $42.29 NYSE:GSK Score: -28.87

https://www.cbsnews.com/news/rectal-cancer-drug-trial-immunotherapy-dostarlimab-study/

https://www.gsk.com/en-gb/media/press-releases/gsk-receives-fda-accelerated-approval-for-jemperli-dostarlimab-gxly-for-adult-patients-with-mismatch-repair-deficient-dmmr-recurrent-or-advanced-solid-tumours/

Recs

0
Member Avatar RES7 (94.97) Submitted: 4/4/2022 1:20:04 AM : Outperform Start Price: $42.88 NYSE:GSK Score: -13.69

sa..finaciaaly free investor

Recs

0
Member Avatar TMFjimhalley (< 20) Submitted: 3/21/2022 4:59:36 PM : Outperform Start Price: $42.70 NYSE:GSK Score: -14.73

The company expects to increase margins after its spinoff from its consumer healthcare division. It also has a strong portfolio in oncology and an above-average dividend for a pharmaceutical company.

Leaderboard

Find the members with the highest scoring picks in GSK.

Score Leader

niwhsa

niwhsa (84.05) Score: +301.42

The Score Leader is the player with the highest score across all their picks in GSK.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
niwhsa 84.05 11/20/2008 Underperform 3Y $17.17 +67.50% +368.93% +301.42 0 Comment
stockpickeraz 26.46 1/16/2009 Underperform 5Y $18.47 +55.73% +341.34% +285.61 0 Comment
stoneyg72 81.82 4/1/2009 Underperform 3W $15.87 +81.30% +359.26% +277.96 0 Comment
lwc123 55.11 1/8/2009 Underperform 3Y $19.84 +45.01% +313.13% +268.12 0 Comment
TRGoodvsEvil 97.97 7/6/2009 Underperform 5Y $17.95 +60.27% +313.50% +253.24 0 Comment
MIKEP75731 38.52 5/22/2009 Underperform 5Y $17.21 +67.14% +315.50% +248.36 1 Comment
longterm007 89.48 10/31/2008 Underperform 5Y $19.53 +47.26% +294.53% +247.27 0 Comment
janiceelaine < 20 10/6/2008 Underperform 3Y $21.33 +34.88% +250.46% +215.58 0 Comment
PurePwnage 96.78 11/27/2009 Underperform 5Y $22.11 +30.10% +237.65% +207.55 0 Comment
allmymarbles 62.89 2/19/2010 Underperform 5Y $20.60 +39.65% +230.87% +191.22 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for GSK.